Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
7.70
Oct 30 • 1:52 PM ET Dollar change-0.41 Percentage change(-5.12%)
Oct 28, 8:05 AMelectroCore seeks FDA 510(k) clearance for Quell neuromodulation device to treat chronic chemotherapy-induced peripheral neuropathy
Index
-
Market Cap
69.38M
Enterprise Value
68.90M
Income
-14.77M
Sales
36.97M
Book/sh
-0.31
Cash/sh
1.11
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
83
IPO
Jun 22, 2018
P/E
-
Forward P/E
-
PEG
-
P/S
1.88
P/B
-
P/C
6.91
P/FCF
-
EV/EBITDA
-
EV/Sales
1.86
Quick Ratio
1.00
Current Ratio
1.21
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-1.70
EPS next Y
-0.62
EPS next Q
-0.27
EPS this Y
16.61%
EPS next Y
54.76%
EPS next 5Y
-
EPS past 3/5Y
29.44% 28.87%
Sales past 3/5Y
55.06% 55.74%
EPS Y/Y TTM
0.24%
Sales Y/Y TTM
33.45%
EPS Q/Q
26.30%
Sales Q/Q
28.03%
Insider Own
32.89%
Insider Trans
-2.94%
Inst Own
13.67%
Inst Trans
11.54%
ROA
-93.41%
ROE
-478.70%
ROIC
-274.03%
Gross Margin
85.47%
Oper. Margin
-37.64%
Profit Margin
-39.96%
SMA20
-8.05%
SMA50
-18.99%
SMA200
-0.56%
Trades
Shs Outstand
9.00M
Shs Float
6.05M
52W High
12.70 -39.41%
52W Low
4.41 74.49%
Volatility
7.48% 8.34%
ATR (14)
0.69
RSI (14)
39.03
Beta
1.18
Rel Volume
0.23
Avg Volume
87.33K
Volume
14,211
Perf Week
9.15%
Perf Month
-25.40%
Perf Quarter
26.35%
Perf Half Y
15.89%
Perf YTD
71.57%
Perf Year
57.68%
Perf 3Y
25.12%
Perf 5Y
-45.40%
Perf 10Y
-
Prev Close
8.11
Price
7.70
Change %
-5.12%
Consensus
Strong Buy
Avg. Price Target
$19.17
Implied Upside
+149.1%
Analysts4incl. previous ratings
Rating Distribution2 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 14, 2020Upgrade
BBTIG Research
Neutral → Buy$3.50-54.5%
Nov 14, 2019Downgrade
JJMP Securities
Mkt Outperform → Mkt Perform
Sep 26, 2019Resumed
CCantor Fitzgerald
Neutral$9+17.0%
May 30, 2019Downgrade
CCantor Fitzgerald
Overweight → Neutral
May 15, 2019Downgrade
BBTIG Research
Buy → Neutral
May 09, 2019Initiated
NNoble Capital Markets
Outperform
Sep 21, 2018Initiated
CCantor Fitzgerald
Overweight
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Errico Thomas J.DirectorSep 14 '26Buy9.825,00049,082363,904Sep 22 07:00 AM
Lev Joshua S.CFO and Interim PresidentAug 21 '26Option Exercise4.5012,00054,00096,889Aug 25 05:30 PM
Lev Joshua S.CFO and Interim PresidentAug 24 '26Option Exercise4.505,00022,50089,889Aug 25 05:30 PM
Lev Joshua S.CFO and Interim PresidentAug 25 '26Option Exercise4.503,00013,50087,889Aug 25 05:30 PM
Lev Joshua S.CFO and Interim PresidentAug 21 '26Sale10.2212,000122,64084,889Aug 25 05:30 PM
Lev Joshua S.CFO and Interim PresidentAug 24 '26Sale9.885,00049,40084,889Aug 25 05:30 PM
Lev Joshua S.CFO and Interim PresidentAug 25 '26Sale9.363,00028,08084,889Aug 25 05:30 PM
Errico Thomas J.DirectorAug 13 '26Buy9.855,00049,272343,332Aug 17 06:19 AM
Goldberger Daniel SFormer Officer & DirectorApr 23 '26Sale6.8080,000544,000211,471Jun 12 06:12 PM
Lev Joshua S.CFO and Interim PresidentMay 28 '26Sale9.006,66760,00384,889May 29 04:05 PM
Joshua S. LevInterim President and Chief FiMay 27 '26Proposed Sale8.916,66759,403May 27 08:40 PM
PATTON THOMAS MDirectorMay 22 '26Proposed Sale7.2485,000615,658May 27 01:17 PM
Errico Thomas J.DirectorMay 21 '26Buy5.999,99259,852360,071May 26 08:52 AM
Lev Joshua S.CFO and Interim PresidentMay 22 '26Sale6.503,00019,50091,556May 22 06:11 PM
Goldberger Daniel SFormer AffiliateMay 14 '26Proposed Sale6.4845,000291,600May 14 03:48 PM
Goldberger Daniel SFormer Affiliate May 05 '26Proposed Sale6.7225,000168,000May 05 10:37 AM
Goldberger Daniel SFormer CEOApr 23 '26Proposed Sale6.1310,00061,300Apr 23 12:43 PM
Goldberger Daniel SFormer Officer and DirectorApr 10 '26Sale6.0216,07296,753291,471Apr 14 04:05 PM
Lev Joshua S.Chief Financial OfficerDec 04 '25Sale5.052,50012,62521,667Dec 05 04:15 PM
Goldberger Daniel SChief Executive OfficerDec 02 '25Buy4.841,0004,840292,565Dec 03 07:00 AM
Lev Joshua S.Chief Financial OfficerNov 12 '25Sale6.182,16613,38623,667Nov 14 04:33 PM
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.
Founder & Independent ChairmanDr. Thomas J. Errico M.D.
CFOMr. Joshua S. Lev
COOMr. Michael Fox
Vice President of HR & Employee SuccessMs. Jennifer A. Hayes
M.D.Dr. Peter S. Staats M.B.A.